UNDERSTANDING AND TARGETING ACQUIRED CHEMORESISTANCE IN HIGH-GRADE SEROUS OVARIAN CANCER

Grant number: 1124309 | Funding period: 2017 - 2019

Completed

Abstract

We recently discovered a mutation in recurrent high-grade serous ovarian cancer that causes profound overexpression of the multidrug resistance pump, MDR1 (Patch et al Nature 2015). In this study I will explore approaches to reverse drug resistance caused by this mutation in recurrent ovarian cancer with a view to utilising alternative treatments to improve patient outcomes.

Related publications (4)

University of Melbourne Researchers